<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0"><channel><title>Individual feed for https://www.2minutemedicine.com/feed/</title><link>https://www.2minutemedicine.com/feed/</link><description>Individual feed output.</description><lastBuildDate>Sat, 09 Aug 2025 01:38:48 GMT</lastBuildDate><generator>PyRSS2Gen-1.1.0</generator><docs>http://blogs.law.harvard.edu/tech/rss</docs><item><title>Ustekinumab may be superior to Vedolizumab for the treatment of Crohn’s disease</title><link>https://www.2minutemedicine.com/ustekinumab-may-be-superior-to-vedolizumab-for-the-treatment-of-crohns-disease/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2018/12/Crohn_Colitis_6264520294-300x150.jpg</image_url><description>1. In patients with Crohn’s disease (CD) of the pouch following ileal-pouch anal anastomosis (IPAA) for medically-refractory ulcerative colitis (UC), ...</description><pubDate>Sat, 09 Aug 2025 00:00:49 GMT</pubDate></item><item><title>#VisualAbstract: Inavolisib Increased Overall Survival in PIK3CA-Mutated Advanced Breast Cancer</title><link>https://www.2minutemedicine.com/visualabstract-inavolisib-increased-overall-survival-in-pik3ca-mutated-advanced-breast-cancer/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2025/08/2MM_VA_17jul2025-300x300.jpg</image_url><description>Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent...</description><pubDate>Fri, 08 Aug 2025 15:00:12 GMT</pubDate></item><item><title>mFOLFIRINOX may have a limited role in pancreatic cancer in Phase II/III trial</title><link>https://www.2minutemedicine.com/mfolfirinox-may-have-a-limited-role-in-pancreatic-cancer-in-phase-ii-iii-trial/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2019/12/pancreas-300x150.jpg</image_url><description>1. In patients with metastatic pancreatic cancer, neither modified fluorouracil, leucovorin, irinotecan and oxaliplatin (mFOLFIRINOX) or S-1, irinotec...</description><pubDate>Fri, 08 Aug 2025 00:00:46 GMT</pubDate></item><item><title>Guselkumab is safe and effective in patients with moderate-to-severe Crohn’s disease</title><link>https://www.2minutemedicine.com/guselkumab-is-safe-and-effective-in-patients-with-moderate-to-severe-crohns-disease/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2016/02/abdominalpain_PD_edited-300x150.jpg</image_url><description>1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable...</description><pubDate>Thu, 07 Aug 2025 22:55:40 GMT</pubDate></item><item><title>Overweight body habitus is associated with higher rates of relapse in children with acute lymphoblastic leukemia</title><link>https://www.2minutemedicine.com/overweight-body-habitus-is-associated-with-higher-rates-of-relapse-in-children-with-acute-lymphoblastic-leukemia/</link><image_url>https://www.2minutemedicine.com/wp-content/uploads/2014/09/Acute_leukemia-ALL-300x151.jpg</image_url><description>1. Among children with acute lymphoblastic leukemia, overweight or obesity at &gt;2 time points (longer duration) was associated with higher rates of rel...</description><pubDate>Thu, 07 Aug 2025 16:00:25 GMT</pubDate></item></channel></rss>